MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-GJ-01-0245949
Market Cap
₹18.11 Cr
MONOPHARMA-SM · NSE
Share Price
₹10.25
0.00% today
Revenue
₹166 Cr
FY 2025-26 · -1.6% YoY
EBITDA
₹3.99 Cr
Margin 2.4%
Net Profit
₹0.34 Cr
FY 2025-26 · -88.9% YoY
P/E (TTM)
24.1x
P/B 0.6x
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹17.67 Cr
Issued & subscribed
About Mono Pharmacare Limited
Data last updated:
Mono Pharmacare Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 October 2022.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24304GJ2022PLC136193. Its GSTIN is 24AAQCM2821E1ZN (Gujarat). It is a listed company as per MCA records. Its shares are listed on NSE: MONOPHARMA.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹17.67 Cr. It is led by directors including Panilam Lakhatariya (Managing Director) and Supal Panilam Lakhatariya.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1A Krinkal Appartment Opp. Mahalaxmi Temple Paldi, Ahmedabad, Gujarat, India – 380007.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹165.69 Cr, a decline of 1.6% compared to the previous year. For the same year it recorded a net profit of ₹34 Lakh (net margin 0.2%) and EBITDA of ₹3.99 Cr (EBITDA margin 2.4%). The net worth stands at ₹31.55 Cr (up 1.1% YoY). Total assets are valued at ₹88.21 Cr (up 3.9% YoY).
The company has about 83 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Mono Pharmacare. As per MCA filings, the company has open charges of ₹16.89 Cr on record. Court records list 14 cases involving the company, including 4 filed by the company and 10 filed against it; 10 cases are pending. The company has 4 deals on record (2 funding rounds, 1 rights issue, 1 ipo), with disclosed funding of ₹10.41 Cr; the latest was in September 2023. Its 10 peer companies in the same principal business activity (wholesale trading) are compared by revenue, 5 larger and 5 smaller; the largest is Sudha Syntex Private Limited with revenue of ₹169.99 Cr.
Mono Pharmacare Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0245949). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website monopharmacareltd.com.
Company details
CIN L24304GJ2022PLC136193
Registration Number 136193
Incorporation Date 17 October 2022
ROC Ahmedabad
Listing Status Listed (NSE: MONOPHARMA)
Company Status Active
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-GJ-01-0245949
CIN history
Mono Pharmacare has one previous CIN (Corporate Identification Number): U24304GJ2022PLC136193. The current CIN is L24304GJ2022PLC136193, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24304GJ2022PLC136193 | Current |
| U24304GJ2022PLC136193 | Previous |
Key People
Panilam Lakhatariya Managing Director Supal Panilam Lakhatariya Director Chintan Trivedi Director Recognitions & Rankings of Mono Pharmacare
Contact details
Mono Pharmacare Limited's registered office is in Ahmedabad, Gujarat. Its website is monopharmacareltd.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1A Krinkal Appartment Opp. Mahalaxmi Temple Paldi, Ahmedabad, Gujarat, India – 380007
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Mono Pharmacare Limited, buy the company report.
Comprehensive company report
Mono Pharmacare Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Mono Pharmacare operates one associated brand: Mono Pharmacare. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Diversified pharmaceutical drugs are distributed across Indian markets. | monopharmacareltd.com |
Business activity
The main business activity of Mono Pharmacare is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Mono Pharmacare Limited, buy the company report.
Financials of Mono Pharmacare Limited
FY 2025-26 filings availableMono Pharmacare Limited reported revenue of ₹165.69 Cr (down 1.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹166 Cr
-1.6% YoY
EBITDA
₹3.99 Cr
-47.7% YoY
Profit After Tax
₹0.34 Cr
-88.9% YoY
Net Worth
₹31.55 Cr
+1.1% YoY
Total Assets
₹88.21 Cr
+3.9% YoY
Total Debt
₹56.50 Cr
+5.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 166 | 168 | 122 | 33.09 |
| Revenue growth | -1.6% | +37.6% | +269.7% | - |
| EBITDA | 3.99 | 7.63 | 6.33 | 2.25 |
| EBITDA margin | +2.4% | +4.5% | +5.2% | +6.8% |
| Profit before tax | 0.57 | 4.45 | 3.23 | 1.33 |
| Net profit | 0.34 | 3.07 | 2.44 | 0.95 |
| Net profit margin | +0.2% | +1.8% | +2.0% | +2.9% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Balance sheet | ||||
| Total assets | 88.21 | 84.88 | 69.61 | 53.62 |
| Net worth | 31.55 | 31.20 | 28.11 | 13.69 |
| Total debt | 56.50 | 53.56 | 41.44 | 39.93 |
| Cash & bank | 0.98 | 0.70 | 0.36 | 0.42 |
| Net working capital | 87.22 | 83.82 | 68.66 | 52.16 |
| Cash flow | ||||
| Cash from operations | 2.68 | (4.30) | (8.77) | (39.54) |
| Cash from investing | (0.38) | (0.23) | 0.40 | (1.16) |
| Cash from financing | (2.01) | 4.86 | 8.32 | 40.73 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 92.91 | 82.64 | 70.72 | 13.92 |
| Revenue growth | +12.4% | +16.9% | +408.1% | - |
| EBITDA | 2.04 | 2.57 | 2.45 | 0.88 |
| EBITDA margin | +2.2% | +3.1% | +3.5% | +6.3% |
| Profit before tax | 0.42 | 3.79 | 2.86 | 0.68 |
| Net profit | 0.34 | 3.10 | 2.44 | 0.55 |
| Net profit margin | +0.4% | +3.8% | +3.5% | +4.0% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Balance sheet | ||||
| Total assets | 58.38 | 54.98 | 41.42 | 25.90 |
| Net worth | 31.55 | 31.20 | 28.11 | 13.40 |
| Total debt | 26.70 | 23.69 | 13.27 | 12.51 |
| Cash & bank | 0.35 | 0.11 | 0.25 | 0.23 |
| Net working capital | 47.29 | 43.85 | 37.66 | 23.68 |
| Cash flow | ||||
| Cash from operations | 0.73 | (0.73) | (10.32) | (13.49) |
| Cash from investing | 0.01 | (7.43) | (1.66) | (2.18) |
| Cash from financing | (0.50) | 8.02 | 12.00 | 15.90 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 166 | 168 | 122 | 33.09 |
| Revenue growth | -1.6% | +37.6% | +269.7% | - |
| Other income | 0.01 | 0.98 | 0.10 | 0.06 |
| Total expenses | 162 | 161 | 116 | 30.84 |
| Employee cost | 0.00 | 2.90 | 2.62 | 0.75 |
| EBITDA | 3.99 | 7.63 | 6.33 | 2.25 |
| EBITDA margin | +2.4% | +4.5% | +5.2% | +6.8% |
| Depreciation | 0.11 | 0.13 | 0.12 | 0.05 |
| Interest | 3.32 | 4.03 | 3.08 | 0.93 |
| Profit before tax | 0.57 | 4.45 | 3.23 | 1.33 |
| Tax | 0.23 | 1.36 | 0.77 | 0.38 |
| Net profit | 0.34 | 3.07 | 2.44 | 0.95 |
| Net profit margin | +0.2% | +1.8% | +2.0% | +2.9% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.67 | 17.67 | 17.67 | 12.37 |
| Reserves & surplus | 13.88 | 13.53 | 10.44 | 1.32 |
| Shareholders' funds (net worth) | 31.55 | 31.20 | 28.11 | 13.69 |
| Minority interest | 0.04 | 0.04 | 0.02 | 0.00 |
| Secured loans | 28.58 | 29.88 | 23.86 | 26.83 |
| Unsecured loans | 27.92 | 23.68 | 17.58 | 13.10 |
| Total debt | 56.50 | 53.56 | 41.44 | 39.93 |
| Total liabilities | 88.21 | 84.88 | 69.61 | 53.62 |
| Assets | ||||
| Gross block | 1.38 | 1.38 | 1.17 | 0.99 |
| Net block | 0.88 | 0.99 | 0.91 | 0.83 |
| Capital work in progress | 0.02 | 0.02 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.57 |
| Inventories | 42.43 | 55.39 | 42.29 | 32.69 |
| Sundry debtors | 74.94 | 41.89 | 31.59 | 21.87 |
| Cash & bank balances | 0.98 | 0.70 | 0.36 | 0.42 |
| Loans & advances | 2.95 | 11.02 | 5.92 | 6.14 |
| Total current assets | 121 | 109 | 80.16 | 61.12 |
| Total current liabilities | 34.08 | 25.18 | 11.50 | 8.96 |
| Net working capital | 87.22 | 83.82 | 68.66 | 52.16 |
| Total assets | 88.21 | 84.88 | 69.61 | 53.62 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.70 | 0.36 | 0.42 | 0.38 |
| Net cash from operating activities | 2.68 | (4.30) | (8.77) | (39.54) |
| Net cash from investing activities | (0.38) | (0.23) | 0.40 | (1.16) |
| Net cash from financing activities | (2.01) | 4.86 | 8.32 | 40.73 |
| Net change in cash | 0.29 | 0.33 | (0.06) | 0.04 |
| Closing cash | 0.98 | 0.70 | 0.36 | 0.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | -1.6% | +37.6% | +269.7% | - |
| EBITDA growth | -47.7% | +20.5% | +181.3% | - |
| PBT growth | -87.2% | +37.8% | +21.4% | +9997.0% |
| Net income growth | -88.9% | +25.8% | +156.8% | - |
| Revenue CAGR (3Y) | +71.1% | - | - | - |
| EBITDA CAGR (3Y) | +21.0% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.2% | +1.8% | +2.0% | +2.9% |
| Return on capital employed | - | +11.0% | +10.2% | +8.4% |
| Return on net worth | - | +10.5% | +11.8% | +13.9% |
| Debt / equity | - | 1.60 | 1.95 | 2.92 |
| Long-term debt / equity | - | 0.73 | 0.71 | 0.91 |
| Interest cover | 85.57 | 53.73 | 49.60 | 42.27 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 132.03 | 113.28 | 66.85 |
| Inventory turnover | - | 3.45 | 3.26 | 2.02 |
| Debtors turnover | - | 4.58 | 4.58 | 3.03 |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 1.53 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 17.66 | 15.91 | 11.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 92.91 | 82.64 | 70.72 | 13.92 |
| Revenue growth | +12.4% | +16.9% | +408.1% | - |
| Other income | 0.00 | 2.54 | 1.70 | 0.20 |
| Total expenses | 90.87 | 80.07 | 68.27 | 13.04 |
| Employee cost | 0.00 | 2.38 | 2.15 | 0.50 |
| EBITDA | 2.04 | 2.57 | 2.45 | 0.88 |
| EBITDA margin | +2.2% | +3.1% | +3.5% | +6.3% |
| Depreciation | 0.08 | 0.08 | 0.08 | 0.02 |
| Interest | 1.54 | 1.24 | 1.21 | 0.38 |
| Profit before tax | 0.42 | 3.79 | 2.86 | 0.68 |
| Tax | 0.08 | 0.69 | 0.42 | 0.13 |
| Net profit | 0.34 | 3.10 | 2.44 | 0.55 |
| Net profit margin | +0.4% | +3.8% | +3.5% | +4.0% |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 17.67 | 17.67 | 17.67 | 12.37 |
| Reserves & surplus | 13.88 | 13.53 | 10.44 | 1.03 |
| Shareholders' funds (net worth) | 31.55 | 31.20 | 28.11 | 13.40 |
| Secured loans | 10.91 | 11.80 | 13.16 | 10.00 |
| Unsecured loans | 15.79 | 11.89 | 0.11 | 2.51 |
| Total debt | 26.70 | 23.69 | 13.27 | 12.51 |
| Total liabilities | 58.38 | 54.98 | 41.42 | 25.90 |
| Assets | ||||
| Gross block | 0.41 | 0.41 | 0.24 | 0.21 |
| Net block | 0.15 | 0.23 | 0.14 | 0.19 |
| Capital work in progress | 0.02 | 0.02 | 0.00 | 0.00 |
| Investments | 10.83 | 10.84 | 3.59 | 1.97 |
| Inventories | 25.04 | 27.79 | 20.99 | 15.18 |
| Sundry debtors | 39.90 | 18.90 | 17.44 | 8.08 |
| Cash & bank balances | 0.35 | 0.11 | 0.25 | 0.23 |
| Loans & advances | 1.23 | 8.14 | 2.96 | 3.35 |
| Total current assets | 66.52 | 54.94 | 41.64 | 26.84 |
| Total current liabilities | 19.23 | 11.09 | 3.98 | 3.16 |
| Net working capital | 47.29 | 43.85 | 37.66 | 23.68 |
| Total assets | 58.38 | 54.98 | 41.42 | 25.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 0.11 | 0.25 | 0.23 | 0.00 |
| Net cash from operating activities | 0.73 | (0.73) | (10.32) | (13.49) |
| Net cash from investing activities | 0.01 | (7.43) | (1.66) | (2.18) |
| Net cash from financing activities | (0.50) | 8.02 | 12.00 | 15.90 |
| Net change in cash | 0.24 | (0.14) | 0.02 | 0.23 |
| Closing cash | 0.35 | 0.11 | 0.25 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +12.4% | +16.9% | +408.1% | - |
| EBITDA growth | -20.6% | +4.9% | +178.4% | - |
| PBT growth | -88.9% | +32.5% | +320.6% | +9997.0% |
| Net income growth | -89.0% | +27.1% | +343.6% | - |
| Revenue CAGR (3Y) | +88.3% | - | - | - |
| EBITDA CAGR (3Y) | +32.4% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.4% | +3.8% | +3.5% | +4.0% |
| Return on capital employed | - | +10.4% | +12.1% | +4.0% |
| Return on net worth | - | +10.4% | +11.8% | +4.0% |
| Debt / equity | - | 0.62 | 0.62 | 0.93 |
| Long-term debt / equity | - | 0.30 | 0.15 | 0.16 |
| Interest cover | 78.57 | 49.80 | 51.05 | 44.19 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 254.28 | 314.31 | 66.29 |
| Inventory turnover | - | 3.39 | 3.91 | 0.92 |
| Debtors turnover | - | 4.55 | 5.54 | 1.72 |
| EPS (₹) | 0.20 | 1.75 | 1.38 | 0.44 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 17.66 | 15.91 | 10.83 |
To see the full year-wise statements and ratios of Mono Pharmacare Limited, buy the company report.
Board of directors of Mono Pharmacare Limited
Mono Pharmacare has 5 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Panilam Lakhatariya | Managing Director | 17 Oct 2022 | 4 Years 0 Months | Current |
| Supal Panilam Lakhatariya | Director | 17 Oct 2022 | 4 Years 0 Months | Current |
| Chintan Trivedi | Director | 22 Mar 2023 | 3 Years 7 Months | Current |
| Drashti Rohit Chande | Director | 11 Jan 2025 | 1 Years 10 Months | Current |
| Nirmala Ranawat Also directs: Alague India Private Limited, Governsphere India Private Limited | Director | 03 Jun 2026 | 0 Years 5 Months | Current |
Peer comparison
Mono Pharmacare Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sudha Syntex Private Limited | ₹169.99 Cr (FY 2025) | 4.0% | Mumbai, Maharashtra, India | |||
| Spanco Metal Private Limited | ₹169.84 Cr (FY 2019) | -67.0% | Kolkata, West Bengal, India | |||
| H P Lifestyle Private Limited | ₹169.62 Cr (FY 2025) | 25.0% | Ahmedabad, Gujarat, India | |||
| Minmet Comtrade Private Limited | ₹169.59 Cr (FY 2025) | 1266.0% | Ranchi, Jharkhand, India | |||
| Sidaan Alloys Private Limited | ₹169.57 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Denali AI India Private Limited | ₹169.28 Cr (FY 2025) | 31.0% | Bangalore, Karnataka, India | |||
| Akashdeep Papers Private Limited | ₹168.93 Cr (FY 2025) | 12.0% | New Delhi, Delhi, India | |||
| Mega Collections Private Limited | ₹168.85 Cr (FY 2025) | -17.0% | Surat, Gujarat, India | |||
| Adiveer Suppliers Private Limited | ₹168.82 Cr (FY 2025) | 8.0% | Lucknow, Uttar Pradesh, India | |||
| Graphic Trades Private Limited | ₹168.78 Cr (FY 2025) | 68.0% | Patna, Bihar, India | |||
| Mono Pharmacare Limitedthis company | ₹165.69 Cr (FY 2026) | ₹34 Lakh | 0.2% | -1.6% | 83 | Ahmedabad, Gujarat, India |
To see the full peer comparison of Mono Pharmacare Limited, buy the company report.
Auditor
Mono Pharmacare Limited is audited by KUMBHAT & CO for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| KUMBHAT & CO | FY 2024 | 001609S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 56.70%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 43.30%.
Sep 2026
QUARTER
56.70% Promoters
43.30% Retail & Others
Promoter holding - history
Now 56.70% · Sep 2026High 56.70% · Dec 2025Low 56.70% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 56.70% | 56.70% | 56.70% | 56.70% |
| Public | 43.30% | 43.30% | 43.30% | 43.30% |
Charges & borrowings
Open charges
₹16.89 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Apr 2025 | 101071738 | Bank of India | ₹7.47 Cr | Open | |
| 19 May 2023 | 100719811 | Bank of India | ₹27.37 Lakh | Open | |
| 19 May 2023 | 100719927 | Bank of India | ₹65 Lakh | Open | |
| 19 May 2023 | 100720026 | Bank of India | ₹5.5 Cr | Open | |
| 29 Apr 2023 | 100713826 | Others | ₹3 Cr | Open |
Total charge records: 5 View all charges
Deals & funding
Mono Pharmacare Limited has 4 deals on record (2 funding rounds, 1 rights issue, 1 ipo), with disclosed funding of ₹10.41 Cr; the latest was in September 2023.
Total deals
4
Funding rounds
2
Rights issue
1
IPO
1
Disclosed funding
₹10.41 Cr
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2023 | IPO | ₹14.84 Cr | Investors: IPO - Mono Pharmacare Limited |
| Mar 2023 | Rights issue | ₹2.35 Cr | Investors: 4 individuals |
| Jan 2023 | Funding round | ₹6.1 Cr | Investors: DLS Export |
| Jan 2023 | Funding round | ₹4.31 Cr | Investors: DLS Export, 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Mono Pharmacare Limited has 14 court cases on record: 4 filed by Mono Pharmacare, 10 filed against it. 10 cases are pending and 4 are disposed.
Total cases
14
Filed by the company
4
Filed against the company
10
Pending
10
Disposed
4
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 13 | 10 | 10 |
| High courts | 1 | 0 | 0 |
Cases on record (5 of 14)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal miscellaneous application | Filed against the company by Lyceum Life Sciences Pvt. Ltd. | Pending |
| District court, Chandigarh | Cheque dishonour complaint | Filed against the company by M/S Logos Pharma | Pending |
| District court, New Delhi, Delhi | Cheque dishonour complaint | Filed against the company by Moneywise Financial Services Pvt Ltd | Pending |
| District court, North West, Delhi | Cheque dishonour complaint | Filed against the company by Admed Pharma Pvt Ltd | Pending |
| District court, Gautam Buddha Nagar, Uttar Pradesh | Criminal case | Filed against the company by Kisetsu Saison Finance India Private Limited | Pending |
To see the full case history of Mono Pharmacare Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Mono Pharmacare Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Mono Pharmacare Limited has a workforce of 83 employees on its EPFO records as of Mar 2025, across 1 active EPFO establishment.
Employee count
83
Active EPFO establishments
1
Employee growth
36.1%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2024-25 | 83 |
| FY 2023-24 | |
| FY 2022-23 |
To see the full employee and EPFO history of Mono Pharmacare Limited, buy the company report.
GST
Mono Pharmacare has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAQCM2821E1ZN | Gujarat | Active | 02 Dec 2022 |
To see the full GST registrations and return filing status of Mono Pharmacare Limited, buy the company report.
Recent activity
Mono Pharmacare Limited has 12 board changes on record since 2022: 9 appointments and 3 cessations. The latest: Nirmala Ranawat was appointed as Director on 03 Jun 2026.
Appointed
Nirmala Ranawat was appointed as Director.
Filing
Mono Pharmacare Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Ceased
Archit Shah ceased to be Director.
AGM
Mono Pharmacare Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Bank Of India amounted to Rs. 7.47 Cr with Charge ID 101071738 was registered on 05 Apr 2025.
Appointed
Drashti Rohit Chande was appointed as Director.
Ceased
Gaurang Girdharlal Vora ceased to be Director.
Appointed
Jitendra Mansukhlal Dasani was appointed as Director.
Ceased
Mitul Manjibhai Sapara ceased to be Director.
Charges
A charge with Bank Of India amounted to Rs. 0.27 Cr with Charge ID 100719811 was registered on 19 May 2023.
Charges
A charge with Bank Of India amounted to Rs. 0.65 Cr with Charge ID 100719927 was registered on 19 May 2023.
Charges
A charge with Bank Of India amounted to Rs. 5.50 Cr with Charge ID 100720026 was registered on 19 May 2023.
8 earlier events are in the company report.
Frequently asked questions
Mono Pharmacare is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 October 2022 (4+ years old) and is registered under CIN L24304GJ2022PLC136193. Listed on NSE: MONOPHARMA.
Mono Pharmacare reported revenue of ₹165.69 Cr for FY 2025-26 (down 1.6% YoY) based on consolidated financials.
Mono Pharmacare has 5 current directors:
- Panilam Lakhatariya - Managing Director
- Supal Panilam Lakhatariya - Director
- Chintan Trivedi - Director
- Drashti Rohit Chande - Director
- Nirmala Ranawat - Director
The latest financial statements of Mono Pharmacare on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2023 are in the company report.
The GSTIN of Mono Pharmacare is 24AAQCM2821E1ZN, registered in Gujarat.
The CIN (Corporate Identification Number) of Mono Pharmacare is L24304GJ2022PLC136193. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Mono Pharmacare is a listed company as per MCA records. Its shares are listed on NSE (symbol: MONOPHARMA).
Mono Pharmacare has 14 court cases on record: 4 filed by the company and 10 filed against it. 10 are pending. Most are in the district courts.
Mono Pharmacare was incorporated on 17 October 2022, making it 4+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Mono Pharmacare has 4 deals on record (2 funding rounds, 1 rights issue, 1 ipo), with disclosed funding of ₹10.41 Cr; the latest was in September 2023.
The peers of Mono Pharmacare by revenue are Sudha Syntex Private Limited, Spanco Metal Private Limited, H P Lifestyle Private Limited, Minmet Comtrade Private Limited, Sidaan Alloys Private Limited and 5 more, all in the same principal business activity (wholesale trading).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages